3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
NSCLC
1
Liver Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Biphenotypic, Acute
1
Kidney Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
aldesleukin
22
Sunitinib
21
Bevacizumab
16
Interleukin-2
14
Everolimus
14
Interferon-alpha
13
Gemcitabine
13
Cyclophosphamide
13
fludarabine phosphate
11
Peripheral Blood Stem Cell Transplantation
9
Sorafenib
8
Filgrastim
8
Axitinib
8
Nivolumab
7
pembrolizumab
6
Ipilimumab
6
Doxorubicin
6
Carboplatin
6
sargramostim
5
cabozantinib
5
Capecitabine
5
Thalidomide
4
Tacrolimus
4
Radiotherapy
4
Radiosurgery
4
Neoadjuvant Therapy
4
Mycophenolic Acid
4
Magnetic Resonance Spectroscopy
4
Erlotinib Hydrochloride
4
Chemotherapy, Adjuvant
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Kidney Neoplasms
×
Tyrosine Kinase Inhibitors
×
Clear all
NCT01649180
2021-08-12
PrE0801
PrECOG, LLC.
Phase 2
Terminated
3 enrolled
7 charts